SkyePharma's Flutiform faces 12-month delay
This article was originally published in Scrip
Executive Summary
More clinical work is needed on SkyePharma's asthma drug, Flutiform (fluticasone propionate plus formoterol fumarate), says the US FDA, causing a potential 12-month delay to the drug's approval.